Developed as a Genomic Data Ecosystem that offers storage of genomic data, expert interpretation and an interchange framework that delivers clinically-relevant genomic interpretation at the point-of-care, CLS will employ lessons learned from the Coriell Personalized Medicine Collaborative (CPMC) research study.
CLS intends to fill the gap between doctors, sequence providers and scientists with expertise in genetic interpretation.
"The intent is that the doctor would order a test like any other diagnostic test they order today," Scott Megill, president of CLS, told the MIT Technology Review while detailing the process. After facilitating the sequencing of the patients' DNA, storing the sample in the CLS gene vault, and brokering the interpretation service, "we will return the genetic result in the human readable form back to the electronic medical record so the doctor can read it and interpret it for the patient," says Megill.
In May, the New Jersey Economic Development Authority (EDA) approved a $1M loan for CLS, noting that the new organization projects to create 26 jobs and is a candidate to lease the EDA's newly renovated Waterfront Technology Center in Camden.
CLS also recently received the prestigious IBM "Entrepreneur of the Year" award for North America. The company was selected as one of only six elite finalists from across the country and attended an intensive three-day summit in California. As part of the program, CLS leadership interfaced with a panel of influential industry experts, investors, and venture capitalists. The selection now qualifies CLS to advance to the Global Finals in February.
To learn more about the work taking place at CLS, click here to visit the company's website.
Click on the links below to read recent news about CLS.
Coriell Life Sciences in the News
Over at Coriell Life Sciences they are making digital copies of people's genome. Just a few years ago, making a copy of your genome would cost tens if not hundreds of thousands of dollars. Nowadays, it is coming down to just a few thousand dollars on the way to maybe a thousand dollars soon. [Full Article]
|"At Coriell Life Sciences, we've identified the necessity to optimize exchanges between healthcare providers, physicians, and patients by focusing on technological innovation. It's becoming increasingly evident that embracing the open cloud model will usher in the next generation of more precise and accurate clinical care." [Full Article]
|"Making clinically relevant genomic data available to physicians at the point-of-care will change the entire construction of the health and medical landscapes," said Scott Megill, President and CEO of CLS. [Full Article]|
|A panel of judges comprised of venture capitalists and tech industry experts selected Coriell Life Sciences as the North American winner of IBM's exclusive "Entrepreneur of the Year" program. CLS will now advance to the Global Finals, to be held in February. [Full Article]|
|"Coriell Life Sciences will develop three products - GeneVault, Gene Exchange and Gene Dose - that will store genomic data, interpret that information, and operate a network that can deliver the data to physicians." [Full Article]|
|"Genomic sequencing might be more common in medicine if doctors had a simple way to send for the test and keep track of the data. That's the hope of Coriell Life Sciences in Camden, New Jersey, a startup that grew out of a partnership between the Coriell Institute for Medical Research and IBM."
|"As far as the physician is concerned, ordering a genetic test will be just like any other diagnostic test, says Scott Megill, CLS president." [Full Article]|
|"Coriell Life Sciences in Camden, New Jersey,will be at the center of a genome ecosystem transmitting queries from physicians to genomic-sequencing interpreters. It will also provide cloud-based storage for each patient's genomic sequence. It sees itself as something of an Amazon.com for genomic sequencing." [Full Article]
"After doctors order a whole-genome sequence, which would be provided by a sequencing service provider, Coriell Life Sciences will harmonize and store that data in a gene vault for the patient. Physicians then will be able to order certain interpretive analyses from third parties on the sequence based on the patient's medical needs." [Full Article]